More genomic alterations in AR and DDR signaling pathways were detected in tumor tissues than in ctDNA, while ctDNA also revealed genomic alterations not detected in tumor tissues, likely because ctDNA can better detect subclonal heterogeneity among tumor cells than a single biopsy or surgery tissue from part of the tumor itself (2, 45–48). This evidence concerns the gene AR and neoplasm.